Skip to main content

Compare Stocks

Date Range: 

 Zentalis PharmaceuticalsMadrigal PharmaceuticalsNGM BiopharmaceuticalsAxsome TherapeuticsAmarin
SymbolNASDAQ:ZNTLNASDAQ:MDGLNASDAQ:NGMNASDAQ:AXSMNASDAQ:AMRN
Price Information
Current Price$58.82$134.70$28.58$58.42$4.38
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.41.51.71.61.6
Analysis Score1.52.43.63.43.2
Community Score3.32.83.42.73.1
Dividend Score0.00.00.00.00.0
Ownership Score1.72.51.71.70.8
Earnings & Valuation Score0.60.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$62.60$167.60$39.11$133.83$10.50
% Upside from Price Target6.43% upside24.42% upside36.85% upside129.09% upside139.73% upside
Trade Information
Market Cap$2.43 billion$2.23 billion$2.20 billion$2.19 billion$1.72 billion
BetaN/A1.191.972.592.58
Average Volume297,746162,137255,723342,3056,371,316
Sales & Book Value
Annual RevenueN/AN/A$103.54 millionN/A$429.76 million
Price / SalesN/AN/A21.26N/A4.01
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/A$27.00 per share$4.96 per share$5.18 per share$1.63 per share
Price / BookN/AN/A5.76N/A2.69
Profitability
Net IncomeN/A$-83,950,000.00$-42,790,000.00$-68,350,000.00$-22,650,000.00
EPSN/A($5.45)($0.85)($2.01)($0.07)
Trailing P/E Ratio0.00N/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A36.50
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-91.64%N/A-2.69%
Return on Equity (ROE)N/A-47.64%-29.47%-62.33%-2.70%
Return on Assets (ROA)N/A-43.21%-25.58%-47.87%-1.72%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.36%N/A
Current RatioN/A6.84%8.01%9.99%2.72%
Quick RatioN/A6.84%8.01%9.99%2.27%
Ownership Information
Institutional Ownership Percentage67.13%74.24%49.56%63.64%37.78%
Insider Ownership PercentageN/A41.89%50.40%26.00%2.75%
Miscellaneous
Employees12442210601,000
Shares Outstanding41.31 million16.59 million77.02 million37.57 million393.44 million
Next Earnings Date5/21/2021 (Estimated)8/5/2021 (Estimated)8/11/2021 (Estimated)8/9/2021 (Estimated)8/3/2021 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl) - GlobeNewswireREDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl) - GlobeNewswire
globenewswire.com - May 15 at 8:36 AM
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th Annual Scientific SessionREDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th Annual Scientific Session
finance.yahoo.com - May 15 at 8:36 AM
Why Amarin Stock Is Tumbling Today - Motley FoolWhy Amarin Stock Is Tumbling Today - Motley Fool
fool.com - May 12 at 3:42 PM
Why Amarin Stock Is Tumbling TodayWhy Amarin Stock Is Tumbling Today
finance.yahoo.com - May 12 at 3:41 PM
Amarin (NASDAQ:AMRN) Shares Gap Down to $4.61Amarin (NASDAQ:AMRN) Shares Gap Down to $4.61
americanbankingnews.com - May 12 at 11:50 AM
Novavax downgraded at JP Morgan on vaccine timeline, Amarin cut to sell at Goldman Sachs; in today’s analyst action - Seeking AlphaNovavax downgraded at JP Morgan on vaccine timeline, Amarin cut to sell at Goldman Sachs; in today’s analyst action - Seeking Alpha
seekingalpha.com - May 12 at 10:41 AM
Amarin Corporation plc (AMRN) Down 4.56% in Premarket Trading - InvestorsObserverAmarin Corporation plc (AMRN) Down 4.56% in Premarket Trading - InvestorsObserver
investorsobserver.com - May 12 at 10:41 AM
Amarin (NASDAQ:AMRN) Rating Lowered to Sell at The Goldman Sachs GroupAmarin (NASDAQ:AMRN) Rating Lowered to Sell at The Goldman Sachs Group
americanbankingnews.com - May 12 at 8:22 AM
Amarin (NASDAQ:AMRN) Lowered to "Sell" at The Goldman Sachs GroupAmarin (NASDAQ:AMRN) Lowered to "Sell" at The Goldman Sachs Group
marketbeat.com - May 12 at 7:21 AM
Patents Are Personal - Above the LawPatents Are Personal - Above the Law
abovethelaw.com - May 11 at 6:34 PM
Amarin Corporation Plc (NASDAQ:AMRN) Will Commercialize VAZKEPA In Q3 2021: Reports Revenues Of $142.2 Million In Q2 2021 - BP JournalAmarin Corporation Plc (NASDAQ:AMRN) Will Commercialize VAZKEPA In Q3 2021: Reports Revenues Of $142.2 Million In Q2 2021 - BP Journal
biopharmajournal.com - May 7 at 10:42 AM
Brokers Set Expectations for Amarin Co. plcs FY2022 Earnings (NASDAQ:AMRN)Brokers Set Expectations for Amarin Co. plc's FY2022 Earnings (NASDAQ:AMRN)
americanbankingnews.com - May 6 at 11:42 AM
Amarin PLC Stock Appears To Be Possible Value Trap - Yahoo FinanceAmarin PLC Stock Appears To Be Possible Value Trap - Yahoo Finance
finance.yahoo.com - May 5 at 4:38 PM
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session - Yahoo FinanceClinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session - Yahoo Finance
finance.yahoo.com - May 5 at 12:03 AM
Relative Strength Alert For Amarin - NasdaqRelative Strength Alert For Amarin - Nasdaq
nasdaq.com - May 5 at 12:03 AM
Is Amarin Corporation plc (AMRN) Stock at the Top of the Biotechnology Industry? - InvestorsObserverIs Amarin Corporation plc (AMRN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
investorsobserver.com - May 4 at 1:51 PM
Clinical Data and Other Research Results Regarding VASCEPA® - GlobeNewswireClinical Data and Other Research Results Regarding VASCEPA® - GlobeNewswire
globenewswire.com - May 4 at 8:50 AM
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific SessionClinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session
finance.yahoo.com - May 4 at 8:50 AM
-$0.04 Earnings Per Share Expected for Amarin Co. plc (NASDAQ:AMRN) This Quarter-$0.04 Earnings Per Share Expected for Amarin Co. plc (NASDAQ:AMRN) This Quarter
americanbankingnews.com - May 3 at 10:22 AM
Amarin Searches For New GC As Top Lawyer Plans To Retire - Law360Amarin Searches For New GC As Top Lawyer Plans To Retire - Law360
law360.com - April 30 at 8:24 PM
Dr Reddys Accuses Amarin Of Illegally Blocking Vascepa API Supply - Generics BulletinDr Reddy's Accuses Amarin Of 'Illegally' Blocking Vascepa API Supply - Generics Bulletin
generics.pharmaintelligence.informa.com - April 30 at 3:23 PM
Analysts Offer Insights on Healthcare Companies: Amarin (AMRN) and Mirum Pharmaceuticals (MIRM) - Smarter AnalystAnalysts Offer Insights on Healthcare Companies: Amarin (AMRN) and Mirum Pharmaceuticals (MIRM) - Smarter Analyst
smarteranalyst.com - April 30 at 10:22 AM
Should You Buy Amarin Corporation plc (AMRN) Stock After it Is Up 3.85% in a Week? - InvestorsObserverShould You Buy Amarin Corporation plc (AMRN) Stock After it Is Up 3.85% in a Week? - InvestorsObserver
investorsobserver.com - April 29 at 11:59 PM
Amarin (AMRN) Q1 2021 Earnings Call Transcript - The Motley FoolAmarin (AMRN) Q1 2021 Earnings Call Transcript - The Motley Fool
fool.com - April 29 at 11:59 PM
Amarin (AMRN) Q1 2021 Earnings Call TranscriptAmarin (AMRN) Q1 2021 Earnings Call Transcript
finance.yahoo.com - April 29 at 11:59 PM
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19 - Yahoo FinanceAmarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19 - Yahoo Finance
finance.yahoo.com - April 29 at 6:59 PM
DateCompanyBrokerageAction
4/19/2021Zentalis PharmaceuticalsSVB LeerinkBoost Price Target
4/1/2021Zentalis PharmaceuticalsHC WainwrightBoost Price Target
1/19/2021Zentalis PharmaceuticalsWedbushInitiated Coverage
12/16/2020Zentalis PharmaceuticalsMorgan StanleyBoost Price Target
9/28/2020Zentalis PharmaceuticalsCantor FitzgeraldInitiated Coverage
4/28/2020Zentalis PharmaceuticalsGuggenheimInitiated Coverage
4/28/2020Zentalis PharmaceuticalsJefferies Financial GroupInitiated Coverage
3/4/2021Madrigal PharmaceuticalsChardan CapitalBoost Price Target
3/2/2021Madrigal PharmaceuticalsOppenheimerLower Price Target
11/23/2020Madrigal PharmaceuticalsEvercore ISIReiterated Rating
11/12/2020Madrigal PharmaceuticalsCanaccord GenuityLower Price Target
11/6/2020Madrigal PharmaceuticalsThe Goldman Sachs GroupBoost Price Target
11/6/2020Madrigal PharmaceuticalsBMO Capital MarketsBoost Price Target
11/5/2020Madrigal PharmaceuticalsPiper SandlerLower Price Target
8/6/2020Madrigal PharmaceuticalsStifel NicolausReiterated Rating
5/22/2020Madrigal PharmaceuticalsB. RileyBoost Price Target
3/5/2020Madrigal PharmaceuticalsCitigroupLower Price Target
3/11/2021NGM BiopharmaceuticalsRaymond JamesBoost Price Target
12/21/2020NGM BiopharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/21/2020NGM BiopharmaceuticalsSmith Barney CitigroupBoost Price Target
3/23/2020NGM BiopharmaceuticalsCowenReiterated Rating
5/12/2021Axsome TherapeuticsBTIG ResearchReiterated Rating
3/2/2021Axsome TherapeuticsMizuhoLower Price Target
12/31/2020Axsome TherapeuticsUBS GroupReiterated Rating
10/1/2020Axsome TherapeuticsWilliam BlairReiterated Rating
9/29/2020Axsome TherapeuticsBank of AmericaInitiated Coverage
4/27/2020Axsome TherapeuticsLADENBURG THALM/SH SHBoost Price Target
4/27/2020Axsome TherapeuticsSunTrust BanksBoost Price Target
9/29/2020AmarinJPMorgan Chase & Co.Initiated Coverage
5/5/2020AmarinNorthland SecuritiesInitiated Coverage
5/4/2020AmarinAegisBoost Price Target
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.